Shenzhen Geno-Immune Medical Institute
72
41
41
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
2.8%
2 terminated/withdrawn out of 72 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (72)
Multiple CAR-T Cell Therapy Targeting AML
Role: lead
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
Role: lead
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
Role: lead
Universal CAR-T Cells Targeting Multiple Myeloma
Role: lead
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Role: lead
Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells
Role: lead
Universal 4SCAR7U Targeting CD7-positive Malignancies
Role: lead
Lentiviral Gene Therapy for CGD
Role: lead
Lentiviral FIX Gene Therapy
Role: lead
Immunotherapy Treating GI Cancer
Role: lead
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Role: lead
Lentiviral FVIII Gene Therapy
Role: lead
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
Role: lead
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Role: lead
CAR-T Immunotherapy Targeting CD19- ALL
Role: lead
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Role: lead
cfMSC Therapy for Diabetes
Role: lead
cfMSC Stem Cell Therapy Targeting COPD
Role: lead
NG2 and DLL3 CAR-T Cells Targeting Melanoma
Role: lead
DLL3 CAR-T Therapy Targeting Brain Tumors
Role: lead